BE2012C047I2 - - Google Patents

Download PDF

Info

Publication number
BE2012C047I2
BE2012C047I2 BE2012C047C BE2012C047C BE2012C047I2 BE 2012C047 I2 BE2012C047 I2 BE 2012C047I2 BE 2012C047 C BE2012C047 C BE 2012C047C BE 2012C047 C BE2012C047 C BE 2012C047C BE 2012C047 I2 BE2012C047 I2 BE 2012C047I2
Authority
BE
Belgium
Prior art keywords
drug
disclosed
compounds
ligand
linker
Prior art date
Application number
BE2012C047C
Other languages
English (en)
French (fr)
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of BE2012C047I2 publication Critical patent/BE2012C047I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2012C047C 2002-07-31 2012-10-31 BE2012C047I2 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40040302P 2002-07-31 2002-07-31
PCT/US2003/024209 WO2004010957A2 (en) 2002-07-31 2003-07-31 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease

Publications (1)

Publication Number Publication Date
BE2012C047I2 true BE2012C047I2 (it) 2022-08-09

Family

ID=31188683

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2012C047C BE2012C047I2 (it) 2002-07-31 2012-10-31

Country Status (16)

Country Link
US (5) US7659241B2 (it)
EP (3) EP2357006B1 (it)
JP (1) JP4741838B2 (it)
AT (1) ATE516818T1 (it)
AU (2) AU2003263964C1 (it)
BE (1) BE2012C047I2 (it)
CA (2) CA2494105C (it)
CY (2) CY1111894T1 (it)
DK (2) DK2357006T3 (it)
ES (3) ES2556641T3 (it)
FR (1) FR12C0066I2 (it)
HU (2) HUE027549T2 (it)
LU (1) LU92133I2 (it)
PT (2) PT2357006E (it)
SI (2) SI2357006T1 (it)
WO (1) WO2004010957A2 (it)

Families Citing this family (777)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
US7244827B2 (en) 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
EP2163256B1 (en) 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP2360169B1 (en) * 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
JP4741838B2 (ja) * 2002-07-31 2011-08-10 シアトル ジェネティクス，インコーポレーテッド 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
JP5356648B2 (ja) * 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
JP4838720B2 (ja) 2003-05-13 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 転移および転移がもたらす骨格関連現象を調節する方法
DK2489364T3 (en) 2003-11-06 2015-03-02 Seattle Genetics Inc Monomethylvaline compounds conjugated to antibodies
US20050175619A1 (en) * 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
AU2005216251B2 (en) * 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1725586B1 (en) * 2004-03-02 2015-01-14 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
US7641903B2 (en) * 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
AU2005295595C1 (en) * 2004-10-15 2012-06-21 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
AU2005332660A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
CA2589374C (en) 2004-11-30 2016-05-03 Curagen Corporation Antibodies directed to gpnmb and uses thereof
US8165517B2 (en) 2005-01-19 2012-04-24 The Trustees Of The University Of Pennsylvania Methods for identifying inhibitors of vascular injury
JP5122441B2 (ja) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド ヒト化抗ｃｄ７０結合剤およびその使用
KR20150126978A (ko) * 2005-06-20 2015-11-13 피에스엠에이 디벨롭먼트 캄파니, 엘엘씨 Ｐｓｍａ 항체-약물 접합체
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
EP3498289A1 (en) 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
SG196786A1 (en) * 2005-07-08 2014-02-13 Elan Pharm Inc Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds
EP3248613B1 (en) * 2005-07-18 2021-12-15 Seagen Inc. Beta-glucuronide drug linker conjugates
NZ566395A (en) 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
JP2009538338A (ja) * 2006-05-22 2009-11-05 イーラン ファーマスーティカルズ、インコーポレイテッド 治療用、農業用及び食品添加用化合物のポリマー複合体の調製
SG172656A1 (en) 2006-05-30 2011-07-28 Genentech Inc Antibodies and immunoconjugates and uses therefor
US8257706B2 (en) * 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
NZ576132A (en) 2006-10-27 2012-04-27 Genentech Inc Antibodies and immunoconjugates and uses therefor
EP2099823B2 (en) 2006-12-01 2022-02-09 Seagen Inc. Variant target binding agents and uses thereof
EP2097534A4 (en) * 2006-12-14 2010-05-12 Medarex Inc HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF
WO2008091701A2 (en) * 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CL2008000420A1 (es) 2007-02-09 2008-06-27 Genentech Inc Anticuerpo anti-robo4; y su uso para modular la angiogenesis.
MX2009009782A (es) * 2007-03-15 2010-09-10 Ludwig Inst Cancer Res Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
KR101540822B1 (ko) 2007-03-27 2015-07-30 씨 레인 바이오테크놀로지스, 엘엘씨 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리
GB0707034D0 (en) 2007-04-12 2007-05-23 St Andrews The Compounds
JP5290276B2 (ja) 2007-05-08 2013-09-18 ジェネンテック， インコーポレイテッド システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
CA2692819A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
KR101486615B1 (ko) 2007-07-16 2015-01-28 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
MX2010001757A (es) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
EP3831380A3 (en) 2007-08-17 2021-12-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
CA2971794C (en) 2007-10-04 2020-03-24 Zymogenetics, Inc. B7 family member zb7h6 and related compositions and methods
US8263083B2 (en) 2007-10-12 2012-09-11 Seattle Genetics, Inc. Combination therapy with antibody-drug conjugates
EP2211904B1 (en) 2007-10-19 2016-08-17 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
JP5580205B2 (ja) 2007-11-19 2014-08-27 セレラ コーポレーション 肺癌マーカーとその使用
EP2078492A1 (de) * 2008-01-11 2009-07-15 Roche Diagnostics GmbH Bandkassette für ein medizinisches Handgerät und Blutzuckermesssystem
CN102083460A (zh) 2008-01-18 2011-06-01 米迪缪尼有限公司 用于位点特异性偶联的半胱氨酸工程化抗体
EP4427805A3 (en) 2008-01-31 2024-12-18 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
EP2265283B1 (en) * 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
SG189776A1 (en) 2008-04-11 2013-05-31 Seattle Genetics Inc Detection and treatment of pancreatic, ovarian and other cancers
KR101892411B1 (ko) 2008-04-30 2018-08-27 이뮤노젠 아이엔씨 가교제 및 그 용도
ES2458541T5 (en) 2008-05-02 2025-08-04 Seagen Inc Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
PL2326350T3 (pl) 2008-09-08 2014-03-31 Psma Dev Company L L C Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP4378482A3 (en) 2009-01-09 2024-09-25 Seagen Inc. Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US8309093B2 (en) * 2009-03-06 2012-11-13 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 24P4C12 proteins
EP2430047B1 (en) 2009-05-13 2018-03-28 i2 Pharmaceuticals, Inc. Neutralizing molecules to influenza viruses
CA2761959C (en) 2009-06-03 2018-09-11 Immunogen, Inc. Conjugation methods
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011038159A2 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
KR20120080611A (ko) 2009-10-06 2012-07-17 이뮤노젠 아이엔씨 효능 있는 접합체 및 친수성 링커
UA108991C2 (uk) 2009-10-23 2015-07-10 Милленниум Фармасьютикалз, Инк. Молекула антитіла до gcc і пов'язані композиції та способи лікування раку
MX338694B (es) 2009-11-30 2016-04-27 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
PL2510011T3 (pl) 2009-12-09 2015-02-27 Inst Nat Sante Rech Med Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
PH12012501545B1 (en) 2010-02-08 2018-08-03 Agensys Inc Antibody drug conjugates (adc) that bind to 161p2f10b proteins
PH12012501680A1 (en) 2010-02-23 2012-11-05 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CA2788289C (en) * 2010-03-02 2018-08-21 Seattle Genetics, Inc. Methods for screening antibodies
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
JP5875083B2 (ja) 2010-04-15 2016-03-02 メディミューン リミテッド 増殖性疾患治療用ピロロベンゾジアゼピン
KR102562175B1 (ko) 2010-04-15 2023-07-31 코디악 사이언시스 인코포레이티드 고분자량 쌍성이온-함유 중합체
EP4039280A1 (en) 2010-04-15 2022-08-10 Seagen Inc. Targeted pyrrolobenzodiazepine conjugates
MX336109B (es) 2010-06-03 2016-01-08 Genentech Inc Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
CN107335062B (zh) 2010-06-08 2021-09-24 基因泰克公司 半胱氨酸改造的抗体和偶联物
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
ES2528956T3 (es) 2010-06-10 2015-02-13 Seattle Genetics, Inc. Nuevos derivados de auristatina y su uso
HRP20171789T1 (hr) 2010-06-15 2017-12-29 Genmab A/S Konjugati humanog protutijela s lijekom protiv tkivnog faktora
JP5953303B2 (ja) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド 改変された等電点を有する抗体
CN103379912B (zh) 2010-09-29 2016-03-16 西雅图基因公司 正羧烷基耳他汀及其应用
KR102166408B1 (ko) 2010-09-29 2020-10-16 어젠시스 인코포레이티드 191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
ES3004351T3 (en) 2010-10-22 2025-03-12 Seagen Inc Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
RU2608646C2 (ru) 2010-12-06 2017-01-23 Сиэтл Генетикс, Инк. Гуманизированные антитела к LIV-1 и их применение для лечения рака
WO2012087962A2 (en) 2010-12-20 2012-06-28 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
WO2012123423A1 (de) 2011-03-16 2012-09-20 Bayer Pharma Aktiengesellschaft N-carboxyalkyl-auristatine und ihre verwendung
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
EP2690955A4 (en) 2011-03-30 2014-10-15 Univ Arizona AURISTATINE TYRAMINE PHOSPHATE SALTS AND AURISTATIN AMINOCHINOLINE DERIVATIVES AND PRODRUGS THEREOF
EP4520771A3 (en) 2011-04-20 2025-07-16 Genmab A/S Bispecifc antibodies against her2
JP6177231B2 (ja) 2011-04-20 2017-08-09 ゲンマブ エー／エス Ｈｅｒ２に対する二重特異性抗体
CN106117312A (zh) 2011-04-21 2016-11-16 西雅图基因公司 新的结合剂‑药物缀合物（adc）及其用途
RU2638806C2 (ru) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms способ мониторинга множественных реакций для выявления терапевтических антител в образцах животных с помощью каркасных сигнатурных пептидов
CN103857689A (zh) 2011-05-19 2014-06-11 哈佛大学的校长及成员们 Osw-1类似物和缀合物，及其用途
ES2643694T3 (es) 2011-05-19 2017-11-23 Inserm (Institut National De La Santé Et De La Recherche Medicale) Anticuerpos anti-HER3 humanos y sus usos
CN103562225B (zh) 2011-05-27 2016-09-28 葛兰素集团有限公司 Bcma（cd269/tnfrsf17）结合蛋白
EP3170821B1 (en) * 2011-05-27 2021-09-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
WO2012166560A1 (en) * 2011-05-27 2012-12-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
MX368966B (es) 2011-06-10 2019-10-23 Mersana Therapeutics Inc Conjugados de proteina-polimero-farmaco.
EA029797B1 (ru) 2011-06-21 2018-05-31 Иммуноджен, Инк. Новые производные майтанзиноида с пептидным линкером и их конъюгаты
US9249228B2 (en) 2011-06-22 2016-02-02 Oribase Pharma Anti-Axl antibodies and uses thereof
CN103747803B (zh) 2011-06-22 2016-10-12 国家医疗保健研究所 抗axl抗体及其用途
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013016714A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
EP2751120B1 (en) 2011-09-20 2018-08-22 MedImmune Limited Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
JP6276186B2 (ja) 2011-09-29 2018-02-07 シアトル ジェネティクス，インコーポレイティド タンパク質が結合した作用物質化合物のインタクト質量の測定
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CA3182462A1 (en) 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013053871A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazepines
CN103987384A (zh) 2011-10-14 2014-08-13 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
WO2013053873A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazepines
WO2013055993A1 (en) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
SG11201401452PA (en) 2011-11-17 2014-06-27 Pfizer Cytotoxic peptides and antibody drug conjugates thereof
US20130224228A1 (en) * 2011-12-05 2013-08-29 Igenica, Inc. Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods
CA2859744A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
EP2793947B1 (en) 2011-12-23 2021-02-03 Innate Pharma Enzymatic conjugation of polypeptides
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
KR102261698B1 (ko) 2012-01-12 2021-06-07 시냅틱스 인코포레이티드 단일층 용량성 이미징 센서들
AU2013209512B2 (en) 2012-01-20 2017-08-03 I2 Pharmaceuticals, Inc. Surrobody cojugates
WO2013119990A2 (en) 2012-02-10 2013-08-15 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
MX2014012889A (es) 2012-05-01 2014-11-14 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17.
EP2849790B1 (en) 2012-05-15 2019-04-10 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
EA037203B1 (ru) 2012-05-15 2021-02-18 Сиэтл Джинетикс, Инк. Конъюгаты антитело-лекарственное средство с самостабилизирующимися линкерами
US8822423B2 (en) * 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
EP2852404B1 (en) 2012-05-21 2017-07-26 Genentech, Inc. ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
US10287564B2 (en) 2012-06-08 2019-05-14 Bioverativ Therapeutics Inc. Procoagulant compounds
JP6498600B2 (ja) 2012-06-08 2019-04-10 ストロ バイオファーマ インコーポレーテッド 部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
JP6514103B2 (ja) 2012-07-06 2019-05-15 ゲンマブ ビー．ブイ． 三重変異を有する二量体タンパク質
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
SI2692865T1 (sl) 2012-07-30 2015-03-31 Nbe-Therapeutics Llc Technology Parc Basel S transpozicijo posredovana identifikacija specifičnih vezavnih ali funkcionalnih proteinov
CA2879670A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
MX2015001399A (es) 2012-08-02 2015-09-07 Genentech Inc Anticuerpos anti-etbr e inmunoconjugados.
CA2882745C (en) 2012-08-23 2022-03-29 Agensys, Inc. Antibody drug conjugates (adc) that bind to 158p1d7 proteins
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
RS56520B1 (sr) 2012-10-12 2018-02-28 Adc Therapeutics Sa Pirolobenzodiazepin-anti-cd22 konjugati antitela
MX364326B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina - anti-psma.
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
EP2906249B1 (en) 2012-10-12 2018-06-27 MedImmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
MX364328B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
KR20200003278A (ko) 2012-10-12 2020-01-08 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
CN104869998A (zh) * 2012-10-16 2015-08-26 恩多塞特公司 含有非天然氨基酸的药物递送缀合物以及其使用方法
JP2016504272A (ja) 2012-10-30 2016-02-12 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 官能化９−ブロモ−カンプトテシン誘導体
US10189906B2 (en) 2012-11-01 2019-01-29 Max-Delrück-Centrum Für Molekulare Medizin Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
ES2656298T3 (es) 2012-11-05 2018-02-26 Pfizer Inc. Análogos de ayustoestatina
EP3564259A3 (en) 2012-11-09 2020-02-12 Innate Pharma Recognition tags for tgase-mediated conjugation
HK1211493A1 (en) 2012-11-15 2016-05-27 恩多塞特公司 Conjugates for treating diseases caused by psma expressing cells
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
JP6334553B2 (ja) 2012-12-10 2018-05-30 メルサナ セラピューティクス，インコーポレイティド タンパク質−高分子−薬剤コンジュゲート
EP2928503B1 (en) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Conjugates of auristatin compounds
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
EP2931305B1 (en) 2012-12-12 2018-11-28 Promega Corporation Compositions and methods for capture of cellular targets of bioactive agents
ES2714951T3 (es) * 2012-12-21 2019-05-30 Bioalliance Cv Enlazadores autoinmoladores hidrófilos y conjugados de los mismos
WO2014096551A1 (en) 2012-12-21 2014-06-26 Glykos Finland Oy Linker-payload molecule conjugates
JP6449777B2 (ja) 2012-12-21 2019-01-09 シアトル ジェネティックス， インコーポレイテッド 抗ｎｔｂ−ａ抗体ならびに関連する組成物および方法
EA201500741A1 (ru) 2013-01-10 2016-01-29 Генмаб Б.В. ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
DK2943511T3 (da) 2013-01-14 2019-10-21 Xencor Inc Nye heterodimeriske proteiner
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
AU2014207549B2 (en) 2013-01-15 2018-12-06 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US9901647B2 (en) 2013-02-28 2018-02-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
HK1219422A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CA2902865A1 (en) 2013-03-14 2014-10-02 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
US11072812B2 (en) 2013-03-15 2021-07-27 Promega Corporation Substrates for covalent tethering of proteins to functional groups or solid surfaces
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
US10168323B2 (en) 2013-03-15 2019-01-01 Promega Corporation Compositions and methods for capture of cellular targets of bioactive agents
US10201614B2 (en) 2013-03-15 2019-02-12 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
RU2015144287A (ru) 2013-03-15 2017-04-24 Эббви Дойчланд Гмбх Унд Ко. Кг Составы конъюгата антитело против egfr-лекарственное средство
HRP20191470T1 (hr) 2013-03-15 2020-01-10 Xencor, Inc. Heterodimerni proteini
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
MX2015012562A (es) 2013-03-15 2016-06-21 Abbvie Inc Purificacion de conjugados anticuerpo-farmaco (cafs).
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
ES2759503T3 (es) 2013-05-02 2020-05-11 Glykos Finland Oy Conjugados de una glicoproteína o un glicano con una carga útil tóxica
CA2910029A1 (en) 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CN105358574B (zh) 2013-05-31 2020-10-16 基因泰克公司 抗壁磷壁酸抗体和缀合物
EP3003387A1 (en) 2013-06-04 2016-04-13 Cytomx Therapeutics Inc. Compositions and methods for conjugating activatable antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
CA2914189C (en) 2013-06-21 2023-03-14 Innate Pharma Enzymatic conjugation of polypeptides
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3027220A1 (en) 2013-08-01 2016-06-08 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
GB2516882A (en) 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
US9552089B2 (en) 2013-08-07 2017-01-24 Synaptics Incorporated Capacitive sensing using a matrix electrode pattern
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
MX377339B (es) 2013-08-28 2025-03-06 Abbvie Stemcentrx Llc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones.
HK1226081A1 (zh) 2013-09-12 2017-09-22 Halozyme, Inc. 修饰的抗表皮生长因子受体抗体及其使用方法
AR097685A1 (es) 2013-09-17 2016-04-06 Genentech Inc Métodos de uso de anticuerpos anti-lgr5
US20150091842A1 (en) 2013-09-30 2015-04-02 Synaptics Incorporated Matrix sensor for image touch sensing
US9298325B2 (en) 2013-09-30 2016-03-29 Synaptics Incorporated Processing system for a capacitive sensing device
US10042489B2 (en) 2013-09-30 2018-08-07 Synaptics Incorporated Matrix sensor for image touch sensing
US9459367B2 (en) 2013-10-02 2016-10-04 Synaptics Incorporated Capacitive sensor driving technique that enables hybrid sensing or equalization
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054992B1 (en) 2013-10-11 2019-08-14 Asana BioSciences, LLC Protein-polymer-drug conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
MX365742B (es) 2013-10-11 2019-06-12 Oxford Biotherapeutics Ltd Anticuerpos conjugados contra ly75 para el tratamiento del cancer.
CA2926586C (en) 2013-10-11 2020-04-07 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
CA3178299A1 (en) 2013-10-11 2015-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tem8 antibodies and their use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015057876A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
AU2014337555C1 (en) * 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
CN105636924B (zh) 2013-10-18 2018-08-07 德国癌症研究中心 前列腺特异性膜抗原(psma)的标记的抑制剂，它们作为显影剂和用于治疗前列腺癌的药剂的用途
US9274662B2 (en) 2013-10-18 2016-03-01 Synaptics Incorporated Sensor matrix pad for performing multiple capacitive sensing techniques
US9290578B2 (en) 2013-10-21 2016-03-22 Genentech, Inc. Anti-Ly6E antibodies and methods of use
US9495046B2 (en) 2013-10-23 2016-11-15 Synaptics Incorporated Parasitic capacitance filter for single-layer capacitive imaging sensors
US9081457B2 (en) 2013-10-30 2015-07-14 Synaptics Incorporated Single-layer muti-touch capacitive imaging sensor
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
JP6449876B2 (ja) 2013-11-07 2019-01-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューレグリンに対して非競合的でアロステリックな抗ヒトｈｅｒ３抗体及びその使用
ES3013992T3 (en) 2013-11-14 2025-04-16 Endocyte Inc Compounds for positron emission tomography
JP6529188B2 (ja) 2013-11-25 2019-06-12 シアトル ジェネティックス， インコーポレイテッド コンジュゲーションのためのｃｈｏ細胞培養物からの抗体の調製
EP3076963A4 (en) * 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
PE20160712A1 (es) 2013-12-13 2016-07-26 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33
KR20160092024A (ko) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
AU2014369019B2 (en) 2013-12-19 2020-09-17 Seagen Inc. Methylene carbamate linkers for use with targeted-drug conjugates
TWI777502B (zh) 2013-12-19 2022-09-11 美商西雅圖遺傳學公司 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
KR20160125361A (ko) 2013-12-27 2016-10-31 자임워크스 인코포레이티드 Ｖａｒ２ｃｓａ－약물 접합체
CN106255513B (zh) 2013-12-27 2022-01-14 酵活有限公司 用于药物偶联物的含磺酰胺连接系统
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
US9827329B2 (en) 2014-01-10 2017-11-28 Birdie Biopharmaceuticals, Inc. Compounds and compositions for immunotherapy
US10323083B2 (en) 2014-01-15 2019-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agents that specifically bind matrilin-3 and their use
US20170043034A1 (en) 2014-01-24 2017-02-16 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
CN105636591B (zh) 2014-01-29 2020-04-07 上海恒瑞医药有限公司 配体-细胞毒性药物偶联物、其制备方法及其应用
FR3017298B1 (fr) 2014-02-07 2016-03-04 Centre Nat Rech Scient Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
KR20230088389A (ko) 2014-02-11 2023-06-19 씨젠 인크. 단백질의 선택적 환원
EP3107557B1 (en) * 2014-02-17 2021-06-09 Seagen Inc. Hydrophilic antibody-drug conjugates
WO2015127407A1 (en) 2014-02-21 2015-08-27 Stemcentrx, Inc. Anti-dll3 antibodies and drug conjugates for use in melanoma
US9798429B2 (en) 2014-02-28 2017-10-24 Synaptics Incorporated Guard electrodes in a sensing stack
CN114262344A (zh) 2014-02-28 2022-04-01 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
CR20210097A (es) 2014-03-21 2022-04-27 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
US10133421B2 (en) 2014-04-02 2018-11-20 Synaptics Incorporated Display stackups for matrix sensor
US9260478B2 (en) 2014-04-04 2016-02-16 Shanghui Hu Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
US9927832B2 (en) 2014-04-25 2018-03-27 Synaptics Incorporated Input device having a reduced border region
US9690397B2 (en) 2014-05-20 2017-06-27 Synaptics Incorporated System and method for detecting an active pen with a matrix sensor
WO2015189477A1 (en) 2014-06-13 2015-12-17 Tenboron Oy Conjugates comprising an anti-egfr1 antibody
FI3166638T3 (fi) 2014-06-13 2025-09-17 Glykos Finland Oy Hyötykuorma-polymeeri-proteiini konjugaatteja
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
WO2015197919A1 (en) 2014-06-25 2015-12-30 Glykos Finland Oy Antibody drug conjugates binding to high-mannose n-glycan
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
HUE048667T2 (hu) 2014-07-11 2020-08-28 Genmab As AXL-hez kötõdõ ellenanyagok
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
EP3194449A1 (en) 2014-07-24 2017-07-26 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
RU2744978C2 (ru) 2014-07-24 2021-03-17 Дженентек, Инк. Способы конъюгации агента с тиольным компонентом в белке, который содержит по меньшей мере одну трисульфидную связь
EP4074735B1 (en) 2014-08-28 2025-05-21 BioAtla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
EA201790521A1 (ru) 2014-09-11 2017-06-30 Сиэтл Дженетикс, Инк. Направленная доставка лекарственных веществ, содержащих третичный амин
JP6943760B2 (ja) 2014-09-12 2021-10-06 ジェネンテック， インコーポレイテッド 抗ｂ７−ｈ４抗体及び免疫複合体
HRP20201719T1 (hr) 2014-09-12 2020-12-25 Genentech, Inc. Protutijela i imunokonjugati anti-her2
AU2015314826A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2016040868A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
BR112017005126B1 (pt) 2014-09-17 2023-10-24 Zymeworks Inc Composto citotóxico e antimitótico, composições, composição farmacêutica, uso do referido composto e uso das referidas composições
HUE049175T2 (hu) 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
AU2015339012B2 (en) 2014-10-31 2020-11-05 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
EP3215513B1 (en) 2014-11-05 2019-05-08 Nerviano Medical Sciences S.r.l. Functionalized morpholinyl anthracycline derivatives
ES2848376T3 (es) 2014-11-19 2021-08-09 Axon Neuroscience Se Anticuerpos de tau humanizados en la enfermedad de Alzheimer
CN104609464B (zh) * 2014-11-21 2017-01-04 中国科学院电工研究所 一种PbS纳米片的制备方法
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016086196A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
RS62332B1 (sr) 2014-11-26 2021-10-29 Xencor Inc Heterodimerna antitela koja vezuju cd3 i cd20
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
HK1243931A1 (zh) 2014-12-03 2018-07-27 F. Hoffmann-La Roche Ag 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
CN107249642A (zh) 2014-12-03 2017-10-13 豪夫迈·罗氏有限公司 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
WO2016094505A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
KR20170093943A (ko) 2014-12-09 2017-08-16 애브비 인코포레이티드 낮은 세포 투과성을 갖는 bcl xl 억제 화합물 및 이를 포함하는 항체 약물 접합체
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
US10175827B2 (en) 2014-12-23 2019-01-08 Synaptics Incorporated Detecting an active pen using a capacitive sensing device
US9778713B2 (en) 2015-01-05 2017-10-03 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
ES2747386T3 (es) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso
AU2016206798A1 (en) 2015-01-14 2017-08-31 Bristol-Myers Squibb Company Benzodiazepine dimers, conjugates thereof, and methods of making and using
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
ES2918425T3 (es) * 2015-01-28 2022-07-15 Sorrento Therapeutics Inc Conjugados de anticuerpo-fármaco
CA2971288A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10472395B2 (en) 2015-03-05 2019-11-12 Sirenas Llc Cyclic peptide analogs and conjugates thereof
JP6764873B2 (ja) 2015-03-09 2020-10-07 アジェンシス，インコーポレイテッド Ｆｌｔ３タンパク質に結合する抗体薬物複合体（ａｄｃ）
KR20170128256A (ko) 2015-03-18 2017-11-22 시애틀 지네틱스, 인크. Cd48 항체 및 이의 접합체
US9939972B2 (en) 2015-04-06 2018-04-10 Synaptics Incorporated Matrix sensor with via routing
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CN106188293A (zh) 2015-04-17 2016-12-07 江苏恒瑞医药股份有限公司 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途
EP3091033A1 (en) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
EP3295171A1 (en) 2015-05-12 2018-03-21 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and kits for labeling, detection and isolation of foxp3+ regulatory t cells, isolated population of foxp3+ regulatory t cells thus obtained and uses thereof
WO2016188911A1 (en) 2015-05-22 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
EP3303391A1 (en) 2015-05-26 2018-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
WO2016189118A1 (en) 2015-05-28 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
JP7269733B2 (ja) 2015-06-12 2023-05-09 レンティジェン・テクノロジー・インコーポレイテッド 操作されたｔ細胞を用いて癌を処置するための方法
WO2015151078A2 (en) 2015-06-15 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Hydrophilic linkers for conjugation
MX2017015814A (es) 2015-06-23 2018-04-10 Squibb Bristol Myers Co Dimeros de benzodiazepina macrociclica, conjugados de los mismos, preparacion y usos.
US9715304B2 (en) 2015-06-30 2017-07-25 Synaptics Incorporated Regular via pattern for sensor-based input device
US9720541B2 (en) 2015-06-30 2017-08-01 Synaptics Incorporated Arrangement of sensor pads and display driver pads for input device
PT3316909T (pt) 2015-06-30 2023-11-22 Seattle Genetics Inc Anticorpos anti-ntb-a e composições e métodos relacionados
US10095948B2 (en) 2015-06-30 2018-10-09 Synaptics Incorporated Modulation scheme for fingerprint sensing
JP6892431B2 (ja) 2015-07-10 2021-06-23 ゲンマブ エー／エス 癌治療用のａｘｌ特異的抗体−薬物コンジュゲート
EP3319936B1 (en) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
AU2016296321B2 (en) 2015-07-22 2022-09-08 Inatherys Anti-TfR antibodies and their use in treating proliferative and inflammatory disorders
CN205028263U (zh) 2015-09-07 2016-02-10 辛纳普蒂克斯公司 一种电容传感器
US10037112B2 (en) 2015-09-30 2018-07-31 Synaptics Incorporated Sensing an active device'S transmission using timing interleaved with display updates
US10722593B2 (en) 2015-10-02 2020-07-28 Sirenas Llc Anti-cancer compounds and conjugates thereof
WO2017062748A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
ES2778651T3 (es) 2015-10-09 2020-08-11 Miltenyi Biotec Technology Inc Receptores de antígeno quimérico y métodos de uso
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
WO2017064034A1 (en) 2015-10-12 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
JP6486316B2 (ja) 2015-11-03 2019-03-20 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗体−薬物複合体（ａｄｃ）およびそれを形成するための方法
FI3377103T4 (fi) 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
EP3383910A1 (en) 2015-11-30 2018-10-10 AbbVie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
CA3006596A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. Anti-hulrrc15 antibody drug conjugates and methods for their use
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
US10067587B2 (en) 2015-12-29 2018-09-04 Synaptics Incorporated Routing conductors in an integrated display device and sensing device
CN106933400B (zh) 2015-12-31 2021-10-29 辛纳普蒂克斯公司 单层传感器图案和感测方法
JP7078536B2 (ja) 2016-01-08 2022-05-31 アルトゥルバイオ， インコーポレイテッド 四価抗ｐｓｇｌ－１抗体とその使用
WO2017121867A1 (en) 2016-01-13 2017-07-20 Genmab A/S Formulation for antibody and drug conjugate thereof
AU2017210327A1 (en) 2016-01-20 2018-08-09 Nbe-Therapeutics Ag ROR1 antibody compositions and related methods
MX390630B (es) * 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
AU2017212739B2 (en) 2016-01-27 2024-03-21 Sutro Biopharma, Inc. Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
MX2018009461A (es) 2016-02-05 2018-12-11 Rigshospitalet Conjugados de anticuerpo-medicamento que se enfocan a la uparap.
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108778329B (zh) 2016-02-17 2022-09-16 西雅图基因公司 Bcma抗体和其用以治疗癌症和免疫病症的用途
EP3419655A1 (en) 2016-02-27 2019-01-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Peptide vaccines comprising self-assembling polymer nanoparticles
TW201740979A (zh) 2016-02-29 2017-12-01 瑪德瑞高製藥公司 熱休克蛋白（ｈｓｐ）９０抑制劑藥物共軛物
TWI871094B (zh) * 2016-03-02 2025-01-21 日商衛材R&D企管股份有限公司 基於艾日布林之抗體-藥物結合物及使用方法
CA3012046C (en) 2016-03-04 2020-11-10 Genentech, Inc. Process for the preparation of an antibody-rifamycin conjugate
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2017162678A1 (en) 2016-03-22 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Humanized anti-claudin-1 antibodies and uses thereof
WO2017165607A1 (en) 2016-03-24 2017-09-28 The Administrators Of The Tulane Educational Fund Conjugates of tacrolimus, their compositions, and their uses
EA201892040A1 (ru) 2016-03-25 2019-04-30 Сиэтл Дженетикс, Инк. Способ получения пегилированных соединений лекарственный препарат - линкер и их промежуточных соединений
ES2948846T3 (es) 2016-03-29 2023-09-20 Toray Industries Derivado peptídico y uso del mismo
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
CN109563164A (zh) 2016-04-15 2019-04-02 生物蛋白有限公司 抗axl抗体、抗体片段和它们的免疫缀合物以及其用途
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
DK3455261T3 (da) 2016-05-13 2022-10-31 Bioatla Inc Anti-ror2-antistoffer, antistoffragmenter, immunkonjugater deraf og anvendelser deraf
HUE053332T2 (hu) 2016-05-17 2021-06-28 Abbvie Biotherapeutics Inc Anti-cMet-antitest-gyógyszer konjugátumok és eljárások alkalmazásukra
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3464294B1 (en) 2016-05-30 2022-07-13 Toxinvent Oü Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3468596A2 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
EP3468598A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
TWI762487B (zh) 2016-06-08 2022-05-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
TW201806626A (zh) 2016-06-08 2018-03-01 美商艾伯維有限公司 抗egfr抗體藥物結合物
US20200338209A1 (en) 2016-06-08 2020-10-29 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
WO2017214233A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
EP3468616A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-egfr antibody drug conjugates
KR102838691B1 (ko) 2016-06-14 2025-07-25 젠코어 인코포레이티드 이중특이적 체크포인트 억제제 항체
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
US11944689B2 (en) 2016-08-09 2024-04-02 Seagen Inc. Drug conjugates with self-stabilizing linkers having improved physiochemical properties
CN106674347B (zh) * 2016-08-16 2019-12-13 滨州医学院 一种新型耳抑素抗体
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3507304B1 (en) 2016-09-02 2024-04-03 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
WO2018045245A1 (en) 2016-09-02 2018-03-08 Sirenas Llc Cyclic peptide analogs and conjugates thereof
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
NZ752412A (en) 2016-10-14 2025-09-26 Xencor Inc Il15/il15rα heterodimeric fc-fusion proteins
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR20230144096A (ko) 2016-10-18 2023-10-13 씨젠 인크. 니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달
KR20240000650A (ko) 2016-10-19 2024-01-02 인벤라 인코포레이티드 항체 구조물
EP3532502A1 (en) 2016-10-25 2019-09-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Monoclonal antibodies binding to the cd160 transmembrane isoform
BR112019008335A2 (pt) 2016-10-28 2020-01-28 Toray Industries, Inc. conjugado de um anticorpo, composição farmacêutica e método para o tratamento e/ou a prevenção de um câncer
BR112019008702A2 (pt) 2016-11-01 2019-07-16 Genmab B.V. polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição.
SG10202104259RA (en) 2016-11-08 2021-06-29 Regeneron Pharma Steroids and protein-conjugates thereof
EP3538221B1 (en) 2016-11-14 2024-10-09 Takeda Pharmaceutical Company Limited Pediatric human dosing of the anti-cd30 antibody-drug conjugate brentuximab vedotin
KR20220147719A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
US10864279B2 (en) 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
AU2017383142A1 (en) 2016-12-22 2019-07-04 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43
KR102015524B1 (ko) * 2016-12-26 2019-08-29 인터올리고 주식회사 압타머-약물 콘쥬게이트 및 그 용도
CN106854245A (zh) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 抗cd30蛋白单克隆抗体及其用途
ES2936803T3 (es) 2017-01-09 2023-03-22 Lentigen Tech Inc Composiciones y métodos para tratar el cáncer con inmunoterapia antimesotelina
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
AU2018220516B2 (en) 2017-02-16 2025-03-06 Sonnet BioTherapeutics, Inc. Albumin binding domain fusion proteins
US20210330801A1 (en) 2017-03-02 2021-10-28 Cadila Healthcare Limited Novel protein drug conjugate formulation
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
EP3601356A1 (en) 2017-03-24 2020-02-05 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
JP7247101B2 (ja) 2017-04-03 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｓｔｅａｐ－１に結合する抗体
CA3056261A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
DK3612537T3 (da) 2017-04-18 2022-08-08 Medimmune Ltd Pyrrolobenzodiazepinkonjugater
EP3612567B1 (en) 2017-04-19 2024-09-11 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
KR20190141666A (ko) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 항-axl 항체-약물 접합체로의 병용 요법
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
US11931414B2 (en) 2017-04-27 2024-03-19 Seagen Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
KR20240046307A (ko) 2017-04-28 2024-04-08 아지노모토 가부시키가이샤 가용성 단백질에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
EP3624854A1 (en) 2017-05-16 2020-03-25 Université de Strasbourg Protein-drug conjugates and their use in the treatment of cancers
EP3624894A1 (en) 2017-05-18 2020-03-25 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
JP7366755B2 (ja) 2017-05-30 2023-10-23 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ 抗ダブルコルチン様キナーゼ１抗体および使用方法
EP3638697A4 (en) 2017-06-12 2021-07-07 Bluefin Biomedicine, Inc. ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ１９ ａｄｃを投与するための投与レジメ
DE112018007259T5 (de) * 2017-06-19 2020-12-24 Sichuan Baili Pharm Co.Ltd Antikörper-Wirkstoff-Konjugat mit einer säurebildenden Selbststabilisierungs-Anbindung
EP3641802A1 (en) 2017-06-22 2020-04-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
CN111315414A (zh) 2017-06-22 2020-06-19 梅尔莎纳医疗公司 产生载药聚合物支架和蛋白-聚合物-药物缀合物的方法
CN111587124B (zh) 2017-06-23 2024-01-12 维洛斯生物股份有限公司 Ror1抗体免疫缀合物
CA3068672A1 (en) 2017-06-28 2019-01-03 The Rockefeller University Anti-mertk agonistic antibody-drug conjugates and uses thereof
CN111132733A (zh) 2017-06-30 2020-05-08 Xencor股份有限公司 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
EP3658588A1 (en) 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
EP3661964A1 (en) 2017-07-31 2020-06-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
MA49979A (fr) 2017-08-09 2020-06-17 Juno Therapeutics Inc Procédés de production de compositions de cellules génétiquement modifiées et compositions associées
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US10501539B2 (en) 2017-09-15 2019-12-10 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-CD19 immunotherapy
RU2020111503A (ru) 2017-09-18 2021-10-20 Сутро Биофарма, Инк. Конъюгаты антитела к рецептору фолиевой кислоты альфа и их применение
JP2020536916A (ja) 2017-10-11 2020-12-17 シアトル ジェネティクス，インコーポレイティド 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法
US11332527B2 (en) 2017-10-12 2022-05-17 Keio University Anti AQP3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (AQP3) and use thereof
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN118345102A (zh) 2017-10-16 2024-07-16 莱蒂恩技术公司 用于用抗cd22免疫治疗来治疗癌症的组合物和方法
CN107759699A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd30抗原的转基因t细胞及其制备方法与应用
EP3703761A1 (en) 2017-11-01 2020-09-09 Seattle Genetics, Inc. Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
AU2018360031B2 (en) 2017-11-03 2025-08-21 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-ROR1 immunotherapy
EP3706805A2 (en) 2017-11-07 2020-09-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2019094637A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
MX2020005319A (es) * 2017-11-22 2020-10-01 Seattle Genetics Inc Ensayo mediado por acido para analizar conjugados de ligando-farmaco.
EP3717069A1 (en) 2017-11-27 2020-10-07 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
EP3717519A4 (en) * 2017-11-29 2021-08-25 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS OF DEPLOYMENT FROM CD2 + CELLS
EP3717518A1 (en) 2017-12-01 2020-10-07 Seattle Genetics, Inc. Humanized anti-liv1 antibodies for the treatment of breast cancer
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
US11766455B2 (en) 2017-12-14 2023-09-26 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
AU2018390418B2 (en) 2017-12-19 2023-12-21 Xencor, Inc. Engineered IL-2 Fc fusion proteins
CN111954677A (zh) 2017-12-20 2020-11-17 莱蒂恩技术公司 用于用免疫治疗来治疗hiv/aids的组合物和方法
EA202091672A1 (ru) 2018-01-08 2021-02-01 Регенерон Фармасьютикалз, Инк. Стероиды и их антитело-конъюгаты
CN111989339A (zh) * 2018-02-20 2020-11-24 西雅图基因公司 疏水性奥瑞他汀f化合物及其缀合物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
AU2019232602B2 (en) 2018-03-07 2025-03-27 Forschungsverbund Berlin E.V. Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates
EP3765525B1 (en) 2018-03-13 2023-07-19 Zymeworks BC Inc. Anti-her2 biparatopic antibody-drug conjugates and methods of use
CA3093422A1 (en) 2018-03-19 2019-09-26 Bioventures, Llc Periostin antibodies and methods of using the same
WO2019183438A1 (en) 2018-03-23 2019-09-26 Seattle Genetics, Inc. Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA3097381A1 (en) 2018-04-17 2019-10-24 Endocyte, Inc. Methods of treating cancer
EP3781599A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
WO2019213386A1 (en) * 2018-05-04 2019-11-07 New Mexico Tech University Research Park Corporation Proteasome inhibitors
CA3099421C (en) 2018-05-04 2025-05-06 Tagworks Pharmaceuticals B.V. COMPOUNDS INCLUDING A BINDER TO INCREASE TRANSCYCLOOCTENE STABILITY
WO2019212356A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B .V. Tetrazines for high click conjugation yield in vivo and high click release yield
IL278522B2 (en) 2018-05-07 2025-10-01 Genmab As Methods for treating cancer with a combination of anti-PD-1 antibody and always an anti-tissue factor antibody drug
JP7519907B2 (ja) 2018-05-07 2024-07-22 ジェンマブ エー／エス 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
SG11202010909RA (en) 2018-05-09 2020-12-30 Regeneron Pharma Anti-msr1 antibodies and methods of use thereof
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
EP3802580A1 (en) 2018-06-05 2021-04-14 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
AU2019285354B2 (en) 2018-06-14 2026-01-15 Ajinomoto Co., Inc. Substance having affinity for antibody, and compound or salt thereof having bioorthogonal functional group
CA3103143A1 (en) 2018-06-14 2019-12-19 Ajinomoto Co., Inc. Compound having affinity substance to antibody, cleavable portion, and reactive group, or salt thereof
JOP20200343A1 (ar) 2018-07-02 2020-12-31 Xencor Inc بروتين ربط مولد ضد مضاد لـ steap1
EP3829648A1 (en) 2018-07-27 2021-06-09 Promega Corporation Quinone-containing conjugates
MX2021002575A (es) 2018-09-11 2021-06-08 Ambrx Inc Conjugados de polipeptidos de interleucina-2 y sus usos.
EP3852811A1 (en) 2018-09-17 2021-07-28 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
CN113396160A (zh) 2018-09-19 2021-09-14 国家医疗保健研究所 治疗对免疫检查点疗法具有抗性的癌症的方法和药物组合物
CN113260630B (zh) 2018-09-20 2024-05-24 莱蒂恩技术公司 用于用抗cd123免疫治疗来治疗癌症的组合物和方法
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
WO2020069184A2 (en) 2018-09-26 2020-04-02 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
CN118806924A (zh) 2018-09-26 2024-10-22 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
JP2022502508A (ja) 2018-10-01 2022-01-11 シージェン・インコーポレーテッド 抗ｃｄ３０抗体薬物複合体療法を使用して末梢性ｔ細胞リンパ腫を処置する方法
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
EP3873534A1 (en) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
CN113227124B (zh) 2018-10-31 2025-04-08 味之素株式会社 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
EP3647419A1 (en) 2018-11-02 2020-05-06 NBE Therapeutics AG Sortase f and its use in methods for conjugation
JP2022512860A (ja) 2018-11-06 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物
EP3883610A4 (en) 2018-11-20 2022-11-02 Cornell University MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY
WO2020113108A1 (en) 2018-11-30 2020-06-04 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd38 immunotherapy
WO2020117373A1 (en) 2018-12-03 2020-06-11 Agensys, Inc. Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
WO2020117257A1 (en) 2018-12-06 2020-06-11 Genentech, Inc. Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
JP7609775B2 (ja) 2018-12-14 2025-01-07 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用
EP3898699A1 (en) 2018-12-19 2021-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
WO2020127968A1 (en) 2018-12-20 2020-06-25 Marino Stephen F Protein-drug conjugate comprising a monomeric form of proteinase 3
GB201820864D0 (en) * 2018-12-20 2019-02-06 J A Kemp Antibody-drug conjugates
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
SG11202107551WA (en) 2019-02-05 2021-08-30 Seagen Inc Anti-cd228 antibodies and antibody-drug conjugates
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
CN117679532A (zh) 2019-02-15 2024-03-12 上海药明合联生物技术有限公司 用于制备具有改善的同质性的抗体-药物缀合物的方法
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
WO2020176497A1 (en) 2019-02-26 2020-09-03 Rgenix, Inc. High-affinity anti-mertk antibodies and uses thereof
MX2021010390A (es) 2019-03-01 2021-11-17 Xencor Inc Anticuerpos heterodimericos que se unen a enpp3 y cd3.
EP3934668A1 (en) 2019-03-06 2022-01-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
SG11202108900WA (en) 2019-03-15 2021-09-29 Medimmune Ltd Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
US20220152179A1 (en) 2019-03-19 2022-05-19 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
CA3134056A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
FI3941946T3 (fi) 2019-03-20 2025-03-28 Univ California Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
US20220362394A1 (en) 2019-05-03 2022-11-17 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
US12459928B2 (en) 2019-05-06 2025-11-04 Seekyo Therapeutic vectors and prodrugs for treating cancers
JP7550794B2 (ja) 2019-05-14 2024-09-13 ジェネンテック， インコーポレイテッド 濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法
WO2020236808A1 (en) 2019-05-20 2020-11-26 Endocyte, Inc. Methods for preparing psma conjugates
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
CU20210096A7 (es) 2019-05-21 2022-06-06 Novartis Ag Moléculas de unión a cd19
EP3976653A1 (en) 2019-05-30 2022-04-06 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-bcma immunotherapy
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
AR119097A1 (es) 2019-06-05 2021-11-24 Seattle Genetics Inc Métodos de purificación de anticuerpos enmascarados
WO2020247572A1 (en) 2019-06-05 2020-12-10 Seattle Genetics, Inc. Masked antibody formulations
CN115135628A (zh) 2019-06-17 2022-09-30 泰克沃尔科斯制药有限公司 快速高效点击释放的化合物
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
MX2022000174A (es) 2019-07-02 2022-05-20 Us Health Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
TW202116810A (zh) 2019-07-22 2021-05-01 美商西雅圖遺傳學股份有限公司 用於治療癌症之人化抗ｌｉｖ１抗體
EP4010372A2 (en) 2019-08-06 2022-06-15 GlaxoSmithKline Intellectual Property Development Limited Biopharmacuetical compositions and related methods
EP4010371A1 (en) 2019-08-08 2022-06-15 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
BR112022002406A2 (pt) 2019-08-12 2022-07-19 Purinomia Biotech Inc Métodos e composições para promover e potencializar respostas imunes mediadas por célula t através do alvejamento de adcc de células que expressam cd39
JP2022548530A (ja) 2019-09-05 2022-11-21 ファルマ、マール、ソシエダード、アノニマ 薬物抗体コンジュゲート
US12545688B2 (en) 2019-09-18 2026-02-10 Systimmune, Inc. Camptothecin derivative and conjugate thereof
KR20220084056A (ko) 2019-09-19 2022-06-21 씨젠 인크. 내재화된 생물학적 활성 화합물 컨쥬게이트로부터의 선택적 약물 방출
JP7659546B2 (ja) 2019-09-25 2025-04-09 シージェン インコーポレイテッド 造血器がんの治療のための抗ｃｄ３０ ａｄｃ、抗ｐｄ－１、および化学療法剤の併用
EP4036149A4 (en) 2019-09-26 2023-10-25 NOF Corporation HETEROBIFUNCTIONAL MONODISPERSPERED POLYETHYLENE GLYCOL WITH PEPTIDE LINKER
BR112022005114A2 (pt) 2019-10-04 2022-06-21 Seagen Inc Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
EP4037710A1 (en) 2019-10-04 2022-08-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
WO2021066869A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
BR112022007216A2 (pt) 2019-10-18 2022-08-23 Genentech Inc Métodos para tratamento de linfoma difuso, kit e imunoconjugado
EP3812008A1 (en) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-competitive antagonist antibody
US20240123081A1 (en) 2019-10-25 2024-04-18 Medimmune, Llc Branched moiety for use in conjugates
TW202134277A (zh) 2019-11-05 2021-09-16 美商再生元醫藥公司 Ｎ—端ｓｃＦｖ多特異性結合分子
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
CN115052890A (zh) 2019-11-07 2022-09-13 展马博联合股份有限公司 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合以治疗癌症的方法
US20250197819A1 (en) 2019-11-22 2025-06-19 Medimmune Limited Fusion proteins comprising an e2 ubiquitin or ubiquitin-like conjugating domain and a targeting domain for specific protein degradation
CN115279789A (zh) 2019-12-06 2022-11-01 真和制药有限公司 破坏gal3和胰岛素受体或整联蛋白的相互作用的抗体及其使用方法
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
JP2023509760A (ja) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
AU2021210079A1 (en) 2020-01-22 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Drug conjugate of Eribulin derivative, preparation method therefor and application thereof in medicine
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
US20230126689A1 (en) 2020-03-06 2023-04-27 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CN115243726B (zh) 2020-03-11 2025-07-15 北京泰德制药股份有限公司 白介素-2多肽偶联物及其使用方法
IL296387B2 (en) 2020-03-19 2024-08-01 Avidity Biosciences Inc Preparations and methods for the treatment of facial, back and arm muscle atrophy
KR20220157425A (ko) 2020-03-25 2022-11-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항체 약물 접합체의 제조 방법
CA3175733A1 (en) 2020-03-25 2021-09-30 Shanghai Hengrui Pharmaceutical Co., Ltd. Pharmaceutical composition comprising antibody drug conjugate and use thereof
EP4126241A1 (en) 2020-03-27 2023-02-08 Novartis AG Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
BR112022019137A2 (pt) 2020-03-27 2023-01-31 Avidity Biosciences Inc Composições e métodos de tratamento de distrofia muscular
AU2021251875A1 (en) 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers
JP7795475B2 (ja) 2020-04-21 2026-01-07 ファルマ、マール、ソシエダード、アノニマ 薬物抗体コンジュゲート
IL297541A (en) 2020-04-24 2022-12-01 Genentech Inc Methods for using anti-cd79b immunoconjugates
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
JP2023528293A (ja) 2020-05-20 2023-07-04 アンスティテュ・クリー 単一ドメイン抗体及びがん治療におけるその使用
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
TW202210084A (zh) 2020-06-05 2022-03-16 新加坡商泰莎治療有限公司 Cd30陽性癌症之治療
WO2021251358A1 (ja) 2020-06-09 2021-12-16 味の素株式会社 修飾フェリチンおよびその製造方法
EP4168437A1 (en) 2020-06-22 2023-04-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
JP2023533937A (ja) 2020-06-29 2023-08-07 ジェンマブ エー／エス 抗組織因子抗体－薬物コンジュゲートおよびがん治療におけるその使用
WO2022029080A1 (en) 2020-08-03 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
AU2021320739A1 (en) 2020-08-04 2023-02-23 Seagen Inc. Anti-CD228 antibodies and antibody-drug conjugates
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
CN112062855B (zh) 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
US20240325517A1 (en) 2020-09-15 2024-10-03 The University Of Montana Compositions and methods targeting filamentous bacteriophage
EP3970752A1 (en) 2020-09-17 2022-03-23 Merck Patent GmbH Molecules with solubility tag and related methods
KR20230079154A (ko) 2020-09-28 2023-06-05 씨젠 인크. 암 치료를 위한 인간화 항-liv1 항체
WO2022079270A1 (en) 2020-10-16 2022-04-21 Université D'aix-Marseille Anti-gpc4 single domain antibodies
AU2021372997A1 (en) 2020-11-05 2023-06-22 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
JP2023548538A (ja) 2020-11-08 2023-11-17 シージェン インコーポレイテッド 併用療法
CN118878693A (zh) 2020-11-23 2024-11-01 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CN114573703A (zh) 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
CN114573702A (zh) 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种新型肿瘤衔接器治疗药物的开发和应用
KR20220082775A (ko) 2020-12-10 2022-06-17 주식회사 유틸렉스 항-pd-1 항체 및 이의 용도
CN117642185A (zh) 2020-12-23 2024-03-01 路德维希-马克西米利安慕尼黑大学 改进的cd30靶向抗体药物偶联物及其用途
CN114685657B (zh) 2020-12-31 2024-08-16 康诺亚生物医药科技（成都）有限公司 一种功能增强型抗体阻断剂的开发及其应用
CN114716548B (zh) 2021-01-05 2024-11-05 (株)爱恩德生物 抗-fgfr3抗体及其用途
JP2024505428A (ja) 2021-01-14 2024-02-06 アンスティテュ キュリー Ｈｅｒ２単一ドメイン抗体バリアントおよびそのｃａｒ
CN116761819A (zh) 2021-01-18 2023-09-15 味之素株式会社 化合物或其盐、以及由它们得到的抗体
AU2022208654B2 (en) 2021-01-18 2026-01-22 Ajinomoto Co., Inc. Compound or salt thereof, and antibody produced using same
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
JP2024506557A (ja) 2021-01-29 2024-02-14 アイオバンス バイオセラピューティクス，インコーポレイテッド 修飾された腫瘍浸潤リンパ球を作製する方法及び養子細胞療法におけるそれらの使用
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
US20250269046A1 (en) 2021-02-26 2025-08-28 Forschungsverbund Berlin E.V. Cellular uptake of large biomolecules enabled by cell-surface-reactive cell-penetrating peptide additives
JP2024512324A (ja) 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
WO2022192403A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
WO2022191283A1 (ja) 2021-03-11 2022-09-15 味の素株式会社 化合物またはその塩、およびそれらにより得られる抗体
EP4310096A4 (en) 2021-03-16 2025-06-25 Ajinomoto Co., Inc. Complex or salt thereof, and method for manufacturing same
TW202300179A (zh) 2021-03-18 2023-01-01 美商西根公司 內化的生物活性化合物偶聯物選擇性釋放藥物
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
WO2022200303A1 (en) 2021-03-23 2022-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of t cell-lymphomas
EP4316527A1 (en) 2021-03-31 2024-02-07 MicroBiopharm Japan Co., Ltd. Method for manufacturing antibody-drug conjugate and enzyme used for same
EP4320153A1 (en) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
JP7717832B2 (ja) 2021-04-10 2025-08-04 ジェンマブ エー／エス Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
CA3216410A1 (en) 2021-04-21 2022-10-27 Guy Dipierro Methods of treatment and dosing of natural killer cell compositions
WO2022223783A1 (en) 2021-04-23 2022-10-27 Forschungsverbund Berlin E.V. Thiol-conjugation with unsaturated phosphorus(v) compounds
AU2022262644A1 (en) 2021-04-23 2023-11-09 Genmab A/S Anti-cd70 antibodies, conjugates thereof and methods of using the same
EP4330379A2 (en) 2021-04-27 2024-03-06 Baylor College of Medicine Virus-specific immune cells expressing chimeric antigen receptors
WO2022232488A1 (en) 2021-04-30 2022-11-03 Celgene Corporation Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi)
AU2022273063A1 (en) 2021-05-12 2023-11-23 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
WO2022248835A1 (en) 2021-05-26 2022-12-01 Oxford Biotherapeutics Ltd Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
EP4370555A4 (en) 2021-07-13 2025-11-12 Truebinding Inc METHODS FOR PREVENTING PROTEIN AGGREGATION
WO2023288236A1 (en) 2021-07-14 2023-01-19 Seagen Inc. Antibody masking domains
IL310392A (en) 2021-08-03 2024-03-01 Glaxosmithkline Ip Dev Ltd Biopharmaceutical preparations and a peptide mapping method for stable isotope labeling
US20250101126A1 (en) 2021-08-05 2025-03-27 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
TW202328188A (zh) 2021-09-03 2023-07-16 美商Ｇｏ治療公司 抗醣化-cmet抗體及其用途
CA3230933A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
EP4400121A1 (en) 2021-09-03 2024-07-17 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CN118339280A (zh) 2021-09-06 2024-07-12 维拉克萨生物技术有限责任公司 用于真核生物中遗传密码子扩展的新型氨酰tRNA合成酶变体
FR3126982B1 (fr) 2021-09-14 2023-09-15 Centre Nat Rech Scient Vecteurs ciblant la beta-d-n-acetylglucosaminidase
CA3231330A1 (en) 2021-09-16 2023-03-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
WO2023041717A1 (en) 2021-09-16 2023-03-23 Aboleris Pharma Anti-human cd45rc binding domains and uses thereof
US20240376200A1 (en) 2021-09-24 2024-11-14 Seagen Inc. Improved Antibody Masking Domains
CN115975030B (zh) 2021-09-30 2023-09-26 杭州邦顺制药有限公司 抗cd39抗体-药物偶联物及其用途
EP4410830A1 (en) 2021-09-30 2024-08-07 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound or salts thereof to be used in producing conjugate or salt thereof
EP4410831A1 (en) 2021-09-30 2024-08-07 Ajinomoto Co., Inc. Regioselective conjugate of functional substance and antibody or salt of said conjugate, and antibody derivative and compound for use in production of said conjugate, or salt of said antibody derivative and compound
WO2023072953A1 (en) 2021-10-26 2023-05-04 Tessa Therapeutics Ltd. Cell lines for producing a retroviral vector encoding a car
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN118302198A (zh) 2021-11-09 2024-07-05 Tubulis 股份有限公司 包含磷(v)和喜树碱部分的偶联物
KR20240100413A (ko) 2021-11-09 2024-07-01 투불리스 게엠베하 인(v) 및 약물 모이어티를 포함하는 접합체
JP2024544508A (ja) 2021-11-09 2024-12-03 トゥルーバインディング，インコーポレイテッド 心臓血管疾患を治療または阻害する方法
EP4433170A1 (en) 2021-11-18 2024-09-25 Oxford BioTherapeutics Ltd Pharmaceutical combinations
WO2023092099A1 (en) 2021-11-19 2023-05-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
DK4186529T3 (da) 2021-11-25 2025-08-25 Veraxa Biotech Gmbh Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
EP4437005A1 (en) 2021-11-25 2024-10-02 Veraxa Biotech GmbH Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
TW202328438A (zh) 2021-12-08 2023-07-16 新加坡商泰莎治療有限公司 淋巴瘤之治療
KR20240119102A (ko) 2021-12-08 2024-08-06 유럽피안 몰레큘러 바이올로지 래보러토리 표적화 접합체의 제조를 위한 친수성 테트라진-관능화 페이로드
WO2023110937A1 (en) 2021-12-14 2023-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
CA3243419A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. CYTOKINE-ASSOCIATED TUMOR-INFILTRATING LYMPHOCYTE COMPOSITIONS AND PROCESSES
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
EP4314031B1 (en) 2022-02-15 2024-03-13 Tagworks Pharmaceuticals B.V. Masked il12 protein
US20230338424A1 (en) 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
US20250231193A1 (en) 2022-04-11 2025-07-17 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t-cell malignancies
EP4507721A1 (en) 2022-04-13 2025-02-19 Tikva allocell Pte. Ltd. Therapeutic t cell product
WO2023198874A1 (en) 2022-04-15 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
WO2023212483A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
TW202408583A (zh) 2022-05-06 2024-03-01 丹麥商珍美寶股份有限公司 使用抗組織因子抗體－藥物共軛體以治療癌症之方法
MA71257A (fr) 2022-06-27 2025-04-30 Foreseen Technology (Beijing) Co., Ltd. Anticorps ciblant itga2 et conjugués anticorps-médicament les comprenant
JPWO2024005123A1 (it) 2022-06-30 2024-01-04
WO2024003310A1 (en) 2022-06-30 2024-01-04 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of acute lymphoblastic leukemia
US12144869B2 (en) 2022-06-30 2024-11-19 Sutro Biopharma, Inc. Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates
WO2024013724A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody-drug conjugates
EP4558823A1 (en) 2022-07-22 2025-05-28 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
KR20240016216A (ko) 2022-07-26 2024-02-06 (주)에임드바이오 항-ror1 항체 및 이의 용도
CA3263188A1 (en) 2022-07-28 2024-02-01 Lentigen Technology, Inc. Chimeric Antigen Receptor Therapies for the Treatment of Solid Tumors
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
EP4536700A4 (en) * 2022-08-22 2025-09-17 Suzhou Bioreinno Biotechnology Ltd Company PROCESS FOR PREPARING AN ANTIBODY HAVING SITE-SPECIFIC MODIFICATIONS
US20260022191A1 (en) * 2022-08-22 2026-01-22 Suzhou Bioreinno Biotechnology Limited Company Method of preparing an antibody with thiol group site-specific modifications and use of tcep
AU2023329412A1 (en) 2022-08-26 2025-03-20 Lentigen Technology, Inc. Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
KR20250053961A (ko) 2022-09-02 2025-04-22 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 토포이소머라제-1 억제제 제약 조성물 및 그의 용도
PE20251282A1 (es) 2022-09-21 2025-05-14 Seagen Inc Anticuerpos que unen cd228
JP2025536268A (ja) 2022-10-12 2025-11-05 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｃｄ８１
IL320221A (en) 2022-10-12 2025-06-01 Tagworks Pharmaceuticals B V Strained bicyclo-nonanes
KR20250089528A (ko) 2022-10-18 2025-06-18 투불리스 게엠베하 신규한 napi2b 항체를 함유하는 신규한 항체 약물 접합체, 치료 방법 및 이의 용도
WO2024083953A1 (en) 2022-10-18 2024-04-25 Tubulis Gmbh Novel anti-tpbg antibody and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
AR130844A1 (es) 2022-10-25 2025-01-22 Merck Sharp & Dohme Llc Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos
EP4608429A1 (en) 2022-10-25 2025-09-03 Peptomyc, S.L. Combination therapy for the treatment of cancer
JP2025537099A (ja) 2022-11-03 2025-11-14 シージェン インコーポレイテッド 抗αＶβ６抗体および抗体－薬物コンジュゲートならびにがんの治療におけるそれらの使用
AU2023396827A1 (en) 2022-12-13 2025-06-19 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
EP4634227A1 (en) 2022-12-13 2025-10-22 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
IL321395A (en) 2022-12-14 2025-08-01 Merck Sharp & Dohme Llc Auristatin cargo-linkers, pharmaceutical compounds, and their uses
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
JP2025542295A (ja) 2022-12-22 2025-12-25 テューブリス ゲーエムベーハー リン（ｖ）部分および薬物を含むコンジュゲート
IL322053A (en) 2023-01-13 2025-09-01 Regeneron Pharma FGFR3 binding molecules and methods of using them
WO2024153789A1 (en) 2023-01-20 2024-07-25 Basf Se Stabilized biopolymer composition, their manufacture and use
WO2024165484A1 (en) 2023-02-06 2024-08-15 Institut National de la Santé et de la Recherche Médicale Enrichment of genetically modified hematopoietic stem cells through multiplex base editing
IL322569A (en) 2023-02-09 2025-10-01 Beone Medicines I Gmbh Self-stabilizing bonding material bracelets
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
AU2024237490A1 (en) 2023-03-10 2025-09-25 Tagworks Pharmaceuticals B.V. Trans-cyclooctene with improved t-linker
AR132178A1 (es) 2023-03-22 2025-06-04 Salubris Biotherapeutics Inc Dominios de unión al antígeno anti-5t4, conjugados anticuerpo-fármaco, y métodos de uso de los mismos
TW202438114A (zh) 2023-03-23 2024-10-01 瑞士商百濟神州瑞士有限責任公司 生物活性結合物、其製備方法及其用途
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies
CN120917041A (zh) 2023-04-04 2025-11-07 味之素株式会社 抗体和功能性物质的缀合物、抗体衍生物以及化合物或它们的盐
EP4692104A1 (en) 2023-04-05 2026-02-11 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt of said conjugate, and antibody intermediate having thiol group or salt of said antibody intermediate
CN116239513B (zh) * 2023-05-05 2023-08-18 天津凯莱英制药有限公司 Mmae关键中间体的制备方法、mmae的制备方法和抗体偶联药物
KR20260007618A (ko) 2023-05-09 2026-01-14 상하이 헨리우스 바이오테크, 인크. 항-표피 성장 인자 수용체(egfr) 항체-약물 접합체 및 이의 응용
CN121285392A (zh) 2023-05-09 2026-01-06 上海复宏汉霖生物技术股份有限公司 一种抗pdl1抗体-药物偶联物及应用
WO2024236156A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d antibodies
WO2024244006A1 (zh) 2023-06-02 2024-12-05 昱言科技(北京)有限公司 靶向itga2的抗体、其抗体药物缀合物以及用途
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
TW202502371A (zh) 2023-06-07 2025-01-16 瓦爾希伯倫私人腫瘤研究基金會 用於治療癌症的與ｂｒａｆ抑制劑的組合療法
CN121335714A (zh) 2023-06-07 2026-01-13 瓦尔希伯伦私人肿瘤研究基金会 用于治疗癌症的与mek抑制剂的组合疗法
AU2024283865A1 (en) 2023-06-08 2025-11-27 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
AU2024304180A1 (en) 2023-06-13 2026-01-08 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
AU2024304014A1 (en) 2023-06-13 2026-01-29 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
WO2025005651A1 (ko) 2023-06-27 2025-01-02 아테온바이오 주식회사 인간화 항-myct1 항체 및 이의 용도
AU2024296940A1 (en) 2023-07-07 2026-01-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
AU2024296516A1 (en) 2023-07-13 2026-01-22 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025021928A1 (en) 2023-07-25 2025-01-30 Merck Patent Gmbh Iduronidase-cleavable compounds
AU2024300552A1 (en) 2023-07-27 2026-01-29 Veraxa Biotech Gmbh Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
WO2025056807A1 (en) 2023-09-15 2025-03-20 Basf Se Stabilized biopolymer composition, their manufacture and use
AU2024201132A1 (en) 2023-09-20 2025-04-10 Uci Therapeutics Inc. Anti-mesothelin antibodies and uses thereof
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
US12540197B2 (en) 2023-10-13 2026-02-03 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025151608A1 (en) * 2024-01-10 2025-07-17 Systimmune, Inc. Connecting units for ligand-drug conjugates and methods of making and using thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025163468A1 (en) 2024-01-30 2025-08-07 Seagen Inc. Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
WO2025174248A1 (en) 2024-02-16 2025-08-21 Tagworks Pharmaceuticals B.V. Trans-cyclooctenes with "or gate" release
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025196639A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody-drug conjugates, and uses thereof
EP4624494A1 (en) 2024-03-29 2025-10-01 Institut Curie Her2 single domain antibody and uses thereof
WO2025223455A1 (en) 2024-04-24 2025-10-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ptk7/b7h3 antibodies and uses thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025238052A1 (en) 2024-05-15 2025-11-20 Institut National de la Santé et de la Recherche Médicale Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
WO2025250825A1 (en) 2024-05-30 2025-12-04 Sutro Biopharma, Inc. Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
WO2025248500A1 (en) 2024-05-31 2025-12-04 Janssen Biotech, Inc. Antibody drug conjugates that target enpp3
WO2025248097A2 (en) 2024-05-31 2025-12-04 Gamamabs Pharma Humanized anti-human her3 antibodies and uses thereof
WO2025257394A1 (en) 2024-06-14 2025-12-18 BioNTech SE Combination therapy for cancer treatment
WO2025264533A1 (en) 2024-06-17 2025-12-26 Adcentrx Therapeutics Inc. Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
US20260000765A1 (en) 2024-06-27 2026-01-01 Lentigen Technology, Inc. CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS
WO2026006784A1 (en) 2024-06-28 2026-01-02 Iovance Biotherapeutics, Inc. Methods of making tumor reactive peripheral blood lymphocytes (trpbl)

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3445518A (en) 1966-05-06 1969-05-20 Warner Lambert Pharmaceutical P-acylphenylethylamines
US4414205A (en) 1981-08-28 1983-11-08 University Patents, Inc. Cell growth inhibitory substances
ES521370A0 (es) 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4764368A (en) * 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
JPH01202700A (ja) 1988-02-09 1989-08-15 Mitsubishi Electric Corp Ｘ線ミラー及びその製造方法
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US4943628A (en) 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
EP0648745A1 (en) 1988-08-12 1995-04-19 Astra Aktiebolag Arylalkylamine having anticonvulsant and neuroprotective properties
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5165923A (en) 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
US5767236A (en) 1990-05-09 1998-06-16 Biomeasure, Inc. Linear therapeutic peptides
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
JP2618597B2 (ja) 1991-08-09 1997-06-11 帝国臓器製薬株式会社 新規なテトラペプチド誘導体
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH06234790A (ja) 1993-02-09 1994-08-23 Teikoku Hormone Mfg Co Ltd 新規テトラペプチドアミド誘導体
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
ES2233928T3 (es) 1993-10-01 2005-06-16 Teikoku Hormone Mfg. Co., Ltd. Derivados de dolastatina.
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
AU4485696A (en) 1995-01-18 1996-08-07 Boehringer Mannheim Gmbh Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen
KR100408909B1 (ko) 1995-04-21 2004-04-29 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규펩티드유도체
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
JPH0977791A (ja) 1995-09-08 1997-03-25 Nippon Kayaku Co Ltd ペプチド誘導体及びその用途
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5741892A (en) 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
EP0961619A4 (en) 1996-09-27 2001-09-26 Bristol Myers Squibb Co HYDROLYSABLE DRUGS FOR THE RELEASE OF ANTI-CANCER DRUGS IN METASTATIC CELLS
JP2002513402A (ja) * 1997-02-25 2002-05-08 アリゾナ ボード オブ リーゼンツ 細胞増殖抑制性の鎖状および環状デプシペプチドであるドラスタチン１６、ドラスタチン１７およびドラスタチン１８の単離と構造決定
US5965537A (en) 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
ATE284412T1 (de) 1998-01-09 2004-12-15 Univ Arizona State Anti-kryptokokkus peptide
US6162930A (en) 1998-03-06 2000-12-19 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US5985837A (en) 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
ES2313883T3 (es) * 1999-02-12 2009-03-16 The Scripps Research Institute Procedimientos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias antiangiogenicas e inmunoterapias.
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
CN101264324A (zh) * 1999-07-12 2008-09-17 杰南技术公司 应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CN100390288C (zh) * 2000-04-11 2008-05-28 杰南技术公司 多价抗体及其应用
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
US20040235068A1 (en) 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
DE60331049D1 (de) 2002-03-01 2010-03-11 Univ Tulane Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
WO2003075855A2 (en) 2002-03-08 2003-09-18 Protein Design Labs, Inc. Antibodies against cancer antigen tmeff2 and uses thereof
WO2003080856A2 (en) 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP4741838B2 (ja) 2002-07-31 2011-08-10 シアトル ジェネティクス，インコーポレーテッド 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
US20050180972A1 (en) 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
AU2003259163B2 (en) 2002-08-16 2008-07-03 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
AU2003299778A1 (en) 2002-12-20 2004-07-22 Protein Design Labs, Inc. Antibodies against gpr64 and uses thereof
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
ES2557769T3 (es) 2003-03-19 2016-01-28 Amgen Fremont Inc. Anticuerpos contra el antígeno del dominio de inmunoglobulina de células T y el dominio 1 de mucina (TIM-1) y usos de los mismos
DK2489364T3 (en) 2003-11-06 2015-03-02 Seattle Genetics Inc Monomethylvaline compounds conjugated to antibodies
AU2005216251B2 (en) * 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1725586B1 (en) 2004-03-02 2015-01-14 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
US7399469B2 (en) 2004-03-26 2008-07-15 Pdl Biopharma, Inc. Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
US7442332B2 (en) * 2004-05-04 2008-10-28 Clopay Plastic Products Company, Inc. Method and apparatus for uniformly stretching thermoplastic film and products produced thereby
EP1756038A1 (en) 2004-06-02 2007-02-28 F.Hoffmann-La Roche Ag Synthesis of amino-alkoxy-heptanoic alkyl ester
HUE030079T2 (en) 2004-09-23 2017-04-28 Genentech Inc Cysteine-manipulated antibodies and conjugates
US20060073152A1 (en) 2004-10-05 2006-04-06 Genentech, Inc. Therapeutic agents with decreased toxicity
CA2589374C (en) 2004-11-30 2016-05-03 Curagen Corporation Antibodies directed to gpnmb and uses thereof
KR20070086128A (ko) 2004-12-13 2007-08-27 에프. 호프만-라 로슈 아게 3-피롤리딘-2-일-프로피온산 유도체의 신규 제조 방법
AU2006210837B2 (en) 2005-01-31 2012-07-12 Genentech, Inc. Anti-EphB2 antibodies and methods using same
US20070098715A1 (en) 2005-03-25 2007-05-03 Seth Ettenberg Antibodies against the tenascin major antigens
KR20150126978A (ko) 2005-06-20 2015-11-13 피에스엠에이 디벨롭먼트 캄파니, 엘엘씨 Ｐｓｍａ 항체-약물 접합체
EP1928912A4 (en) * 2005-09-07 2010-02-24 Medimmune Inc EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS
AU2006315580A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen
WO2007062138A2 (en) 2005-11-23 2007-05-31 Applera Corporation Methods and compositions for treating diseases targeting human prominin-1(cd133)
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados

Also Published As

Publication number Publication date
PT1545613E (pt) 2011-09-27
FR12C0066I1 (it) 2012-12-14
CY2013004I1 (el) 2015-11-04
EP2353611A3 (en) 2011-10-19
EP1545613A4 (en) 2008-10-15
SI2357006T1 (sl) 2016-01-29
US8906376B2 (en) 2014-12-09
CA2802205C (en) 2016-01-19
HUS1300002I1 (hu) 2016-08-29
US20080213289A1 (en) 2008-09-04
AU2010201459A1 (en) 2010-05-06
US7829531B2 (en) 2010-11-09
US20060074008A1 (en) 2006-04-06
ES2544527T3 (es) 2015-09-01
ES2556641T3 (es) 2016-01-19
AU2003263964B2 (en) 2010-01-14
CA2494105C (en) 2013-04-02
SI1545613T1 (sl) 2011-11-30
EP2353611A2 (en) 2011-08-10
CA2494105A1 (en) 2004-02-05
ATE516818T1 (de) 2011-08-15
US7659241B2 (en) 2010-02-09
US7851437B2 (en) 2010-12-14
US20100062008A1 (en) 2010-03-11
US20110064753A1 (en) 2011-03-17
DK1545613T3 (da) 2011-11-14
WO2004010957A2 (en) 2004-02-05
AU2003263964A1 (en) 2004-02-16
CA2802205A1 (en) 2004-02-05
WO2004010957B1 (en) 2004-08-19
EP2353611B1 (en) 2015-05-13
HUE027549T2 (hu) 2016-10-28
AU2010201459B2 (en) 2012-12-06
JP4741838B2 (ja) 2011-08-10
EP1545613B9 (en) 2012-01-25
CY1111894T1 (el) 2015-11-04
LU92133I9 (it) 2019-01-04
LU92133I2 (fr) 2013-03-18
US20090324621A1 (en) 2009-12-31
WO2004010957A3 (en) 2004-06-10
DK2357006T3 (en) 2015-12-21
ES2369542T3 (es) 2011-12-01
EP2357006A3 (en) 2011-10-19
EP1545613A2 (en) 2005-06-29
HK1157180A1 (en) 2012-06-29
CY2013004I2 (el) 2017-09-13
FR12C0066I2 (fr) 2013-08-16
AU2003263964C1 (en) 2010-08-19
EP1545613B1 (en) 2011-07-20
EP2357006B1 (en) 2015-09-16
PT2357006E (pt) 2016-01-22
EP2357006A2 (en) 2011-08-17
JP2006500333A (ja) 2006-01-05

Similar Documents

Publication Publication Date Title
LU92133I9 (it)
DK1594542T3 (da) Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
MY137552A (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
EP1507556A4 (en) CALICHEAMICINE DERIVATIVE VECTOR-TYPE CONJUGATES
WO2007100385A3 (en) Macrocyclic depsipeptide antibody-drug conjugates and methods
WO2004005326A3 (de) Tubulysinkonjugate
WO2005032454A3 (en) Anti-muc-1 single chain antibodies for tumor targeting
DK1660650T3 (da) Forbedrede Sso7-polymerase-konjugat-proteiner
SI1797893T1 (sl) Protitelesa proti fosforilholinskim konjugatom
PT1572087E (pt) Anticorpos contra o antigénio de cancro tmeff2 e suas utilizações
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
WO2005000858A3 (en) Bisphosphonate complexes
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
MXPA01010395A (es) Conjugados de cobalamina que son utiles como agentes antitumor.
WO2005048822A3 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
CY1117037T1 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματικης ασθενεια
PT1708693E (pt) Composições farmacêuticas contendo complexos de platina com xantatos secundários e suas utilizações terapêuticas
AU2002354872A1 (en) Novel chelating agents and conjugates thereof, their synthesis and use as diagnostic and therapeutic agents